OM:INDEX

Stock Analysis Report

InDex Pharmaceuticals Holding

Executive Summary

InDex Pharmaceuticals Holding AB (publ) develops pharmaceuticals for patients with ulcerative colitis.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • InDex Pharmaceuticals Holding is not covered by any analysts.

Share Price & News

How has InDex Pharmaceuticals Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.2%

OM:INDEX

0.4%

SE Pharmaceuticals

2.2%

SE Market


1 Year Return

16.8%

OM:INDEX

-7.3%

SE Pharmaceuticals

-2.1%

SE Market

INDEX outperformed the Pharmaceuticals industry which returned -6.3% over the past year.

INDEX outperformed the Market in Sweden which returned -1.9% over the past year.


Share holder returns

INDEXIndustryMarket
7 Day-2.2%0.4%2.2%
30 Day-9.2%-3.8%-3.4%
90 Day-3.9%-7.1%0.5%
1 Year16.8%16.8%-5.4%-7.3%2.0%-2.1%
3 Yearn/a12.5%8.6%24.9%6.4%
5 Yearn/a-16.3%-22.1%45.2%14.5%

Price Volatility Vs. Market

How volatile is InDex Pharmaceuticals Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InDex Pharmaceuticals Holding undervalued based on future cash flows and its price relative to the stock market?

21.79x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for InDex Pharmaceuticals Holding to establish if it is available at moderate discount.

Unable to calculate intrinsic value for InDex Pharmaceuticals Holding to establish if it is available at substantial discount.


Price Based on Earnings

InDex Pharmaceuticals Holding is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.

InDex Pharmaceuticals Holding is loss making, we can't compare the value of its earnings to the Sweden market.


Price Based on Expected Growth

Unable to calculate PEG ratio for InDex Pharmaceuticals Holding, we can't assess if its growth is good value.


Price Based on Value of Assets

InDex Pharmaceuticals Holding is overvalued based on assets compared to the SE Pharmaceuticals industry average.


Next Steps

Future Growth

How is InDex Pharmaceuticals Holding expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InDex Pharmaceuticals Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has InDex Pharmaceuticals Holding performed over the past 5 years?

-29.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

InDex Pharmaceuticals Holding does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare InDex Pharmaceuticals Holding's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare InDex Pharmaceuticals Holding's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if InDex Pharmaceuticals Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if InDex Pharmaceuticals Holding has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if InDex Pharmaceuticals Holding improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is InDex Pharmaceuticals Holding's financial position?


Financial Position Analysis

InDex Pharmaceuticals Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

InDex Pharmaceuticals Holding has no long term commitments.


Debt to Equity History and Analysis

InDex Pharmaceuticals Holding has no debt.

InDex Pharmaceuticals Holding has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

InDex Pharmaceuticals Holding has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

InDex Pharmaceuticals Holding has less than a year of cash runway based on current free cash flow.

InDex Pharmaceuticals Holding has less than a year of cash runway if free cash flow continues to grow at historical rates of 32.1% each year.


Next Steps

Dividend

What is InDex Pharmaceuticals Holding's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate InDex Pharmaceuticals Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate InDex Pharmaceuticals Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as InDex Pharmaceuticals Holding has not reported any payouts.

Unable to verify if InDex Pharmaceuticals Holding's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as InDex Pharmaceuticals Holding has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of InDex Pharmaceuticals Holding's salary, the management and board of directors tenure and is there insider trading?

3.6yrs

Average management tenure


CEO

Peter Zerhouni (47yo)

3.6yrs

Tenure

0

Mr. Peter Zerhouni, M.Sc., BSc has been Chief Executive Officer at InDex Pharmaceuticals Holding AB (publ) since 2016. Mr. Zerhouni has been Chief Executive Officer of InDex Pharmaceuticals AB and InDex Di ...


Management Age and Tenure

3.6yrs

Average Tenure

56yo

Average Age

The tenure for the InDex Pharmaceuticals Holding management team is about average.


Board Age and Tenure

3.6yrs

Average Tenure

67yo

Average Age

The tenure for the InDex Pharmaceuticals Holding board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

Buykr78,60020 May 19
Johan Giléus
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares10,000
Max Pricekr7.86
Buykr185,23401 Mar 19
Stig Pedersen
EntityIndividual
Role
Member of the Board of Directors
Director
Shares23,809
Max Pricekr7.78

Ownership Breakdown


Management Team

  • Per-Olof Gunnesson (74yo)

    Consultant

    • Tenure: 2.3yrs
  • Peter Zerhouni (47yo)

    Chief Executive Officer

    • Tenure: 3.6yrs
  • Pernilla Sandwall (56yo)

    Chief Operating Officer

    • Tenure: 7.5yrs
  • Thomas Knittel (57yo)

    Chief Medical Officer

    • Tenure: 7.6yrs
  • Johan Giléus (54yo)

    Chief Financial Officer

    • Tenure: 2.3yrs

Board Members

  • Lennart Hansson (63yo)

    Director

    • Tenure: 3.6yrs
    • Compensation: kr200.00k
  • Hans Wigzell (81yo)

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Uli Hacksell (69yo)

    Director

    • Tenure: 3.6yrs
    • Compensation: kr200.00k
  • Stig Pedersen (58yo)

    Director

    • Tenure: 3.6yrs
    • Compensation: kr200.00k
  • Christopher Hawkey

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Wenche Rolfsen (67yo)

    Chairman

    • Tenure: 3.6yrs
    • Compensation: kr400.00k
  • Gunther Hartmann

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Markus Neurath

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Robert Löfberg

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs

Company Information

InDex Pharmaceuticals Holding AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InDex Pharmaceuticals Holding AB (publ)
  • Ticker: INDEX
  • Exchange: OM
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr544.748m
  • Shares outstanding: 68.78m
  • Website: https://www.indexpharma.com

Number of Employees


Location

  • InDex Pharmaceuticals Holding AB (publ)
  • Tomtebodavägen 23a
  • Stockholm
  • Stockholm County
  • 171 77
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INDEXOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKOct 2016

Biography

InDex Pharmaceuticals Holding AB (publ) develops pharmaceuticals for patients with ulcerative colitis. The company’s lead drug is Cobitolimod, which is in late stage clinical development for moderate to se ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 22:16
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.